10 Best AI Driven Biotech Stocks to Invest In

7. Erasca Inc. (NASDAQ:ERAS)

Erasca Inc. (NASDAQ:ERAS) is one of the 10 best AI driven biotech stocks to invest in.

As of the close of play on June 5, consensus sentiment for Erasca Inc. (NASDAQ:ERAS) was strongly bullish. Based on a 1-year target price of $21, the stock offers an upside potential of more than 75% at the current level. It received Buy ratings from 8 of the 10 analysts who provided coverage, while 2 analysts gave Hold calls.

On June 4, early clinical trial results for Erasca Inc. (NASDAQ:ERAS) pan-RAS treatment ERAS-0015 indicate legitimacy, and medical experts in the field have provided highly positive feedback on its performance. Because of this, the primary discussion among investors is no longer about whether the drug actually functions, but rather how commercially effective it can be.

Bank of America Securities noted that the stock’s current price gives a much fairer picture of the underlying risks involved. Consequently, the firm upgraded the stock from Underperform to a Neutral rating. In the process, it also raised the price target from $9 to $16, leading to an adjusted upside of almost 34%.

Back on May 12, Mizuho cut down its target price for Erasca Inc. (NASDAQ:ERAS) from $28 to $26, which still yields more than 117% upside potential for investors. The firm also maintained its Outperform rating for the stock.

Erasca Inc. (NASDAQ:ERAS) is a clinical-stage precision oncology company that focuses on developing and commercializing therapies for RAS/MAPK pathway-driven cancers. The product pipeline includes ERAS-0015, ERAS-4001, and ERAS-12. It has established licensing agreements with multiple pharmaceutical partners for the development of additional therapeutic compounds. These include naporafenib, ERAS-601, and ERAS-007.